세계의 안티트롬빈 시장(2023-2030년)

Market Overview

The Global Antithrombin Market reached US$ 545 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 775.7 million by 2030. The global antithrombin market is expected to exhibit a CAGR of 4.6% during the forecast period 2023-2030.

The increasing prevalence of cardiovascular diseases, rising demand for antithrombin therapy in the treatment of hereditary antithrombin deficiency, growing research and development activities in the field of antithrombin, and growing adoption of antithrombin in surgical procedures are some of the antithrombin market trends that will influence the Global Antithrombin Market.

For instance, a study conducted by researchers at the University of California, San Francisco, published in the journal Science Translational Medicine, Antithrombin deficiency is a hereditary disease that can lead to blood clotting. Scientists have created a gene-editing therapy that transforms blood cells from afflicted patients into pluripotent stem cells (iPSCs) using the CRISPR-Cas9 gene-editing technology to treat this disease.

Then altered iPSCs are transformed into hepatocytes, liver cells that make antithrombin. These hepatocytes are subsequently implanted into mice with antithrombin deficiencies, reducing blood clot formation. This work demonstrates CRISPR-Cas9's potential for repairing genetic abnormalities and holds hope for developing innovative therapeutics for hereditary antithrombin deficiency.

Antithrombin (AT) is a 464 amino acid glycoprotein synthesized in the liver. It has three disulfide bonds and four glycosylation sites. AT is a serpin family member that functions as a serine protease inhibitor. It can bind to and deactivate numerous proteases involved in the coagulation process. Among the proteases are thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa. AT's inhibitory activity extends to proteins C and S, both of which are essential anticoagulant proteins.

The rising incidence of venous thromboembolism (vte), growing demand for antithrombin as a therapeutic agent in various clinical settings, and development of new antithrombin products and therapies are the factors expected to drive the global antithrombin market over the forecast period.

Development of new antithrombin product, for instance, Octapharma, is conducting a clinical trial to evaluate the efficacy of Atenativ in individuals having surgery or delivery who have congenital antithrombin deficiency. These are the factors influencing the global antithrombin market.

Market Dynamics

Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.

On a global level, cardiovascular disease is a major cause of mortality and disability. Its development is influenced by several variables, including as high blood pressure, high cholesterol, smoking, and obesity.

For instance, according to the American Heart Association's Heart Disease and Stroke Statistics report of 2023, 928,741 deaths were seen in the U.S. in 2020 for cardiovascular disease, in which coronary heart disease (CHD) held 41.2% of deaths, followed by strokes. Therefore owing to these reasons, the growing prevalence of cardiovascular disease will drive the global antithrombin market over the forecast period.

The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.

Various factors contribute to the higher cost of antithrombin drugs. In contrast to synthetic medications, they start off as expensive source materials since they are made from pooled human plasma. Second, the production of antithrombin products is more complicated and expensive overall due to the high degrees of purification and concentration required.

Moreover, compared to other therapies, antithrombin medicines have a smaller market and less competition, which results in less price competition. Last but not least, antithrombin products mainly treat a rare disease termed severe antithrombin deficiency, further limiting the global antithrombin market size and contributing to higher prices.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant effects on the Global Antithrombin Market. Antithrombin demand has decreased due to a decline in surgical operations and diagnosis of illnesses such as venous thromboembolism (VTE). The market is expected to grow in the future despite these obstacles. Several reasons, such as the rising incidence of cardiovascular disorders, more knowledge of the benefits of antithrombin therapy, and improvements in the creation of novel antithrombin medicines, will influence this expansion.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has hurt the global antithrombin market, which has reduced its supply. Sanctions on Russia, supply chain hiccups, and decreased output are just a few of the causes that contributed to this fall. Antithrombin costs have increased due to the reduced availability, making it more difficult for patients to purchase the medication.

Due to several circumstances, the conflict has also led to a decline in the demand for antithrombin. There is less access to healthcare services, less money to spend, and more fear and worry among those impacted by the violence. The Russia-Ukraine conflict is anticipated to have a short-term detrimental effect on the world antithrombin market.

Segment Analysis

The Global Antithrombin Market is segmented based on usage, source, route of administration, type, and region.

The Parenteral segment is expected to hold a dominant position for the global antithrombin market over the forecast period.

The Parenteral route accounted for the highest market share, accounting for approximately 64.4% of the antithrombin market in 2022. The preferred route of administration for antithrombin drugs in the Parenteral route is intravenous. Because the intravenous injection is frequently utilized to deliver antithrombin into the blood circulation swiftly, it provides prompt and effective therapy, it is commonly preferred for individuals with severe antithrombin insufficiency.

Thrombate III, a pure human antithrombin III product, is a sterile and stable lyophilized preparation. It is used to treat both primary and acquired antithrombin insufficiency. It is made from pooled units of human plasma collected from healthy donors. Thrombate III contains no preservatives and should only be taken intravenously. Thus, owing to the above factors, the market segment is expected to hold the largest market share for global antithrombin market over the forecast period.

Geographical Analysis

North America Holds a Dominant Position in the Global Antithrombin Market.

North America is expected to hold around 38.8% of the total market share throughout the forecast period, as the chance of having thrombotic illnesses such as deep vein thrombosis (DVT), pulmonary embolism, and stroke rises as people age. Geriatric patients may have several comorbidities, surgeries, and limited mobility, all of which increase their risk of blood clot development. With the baby boomer generation approaching retirement age and beyond, the United States has a considerable aging population.

For instance, according to the United States Census Bureau's 2023 report, the 2021 American Community Survey indicated 55,892,014 persons aged 65 and older in the U.S., or 16.8% of the total population of 331,893,745.

Moreover, the increasing awareness about the benefits of antithrombin therapy and the rising number of patients undergoing surgery, also the presence of a major market player in the region, is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma, among others.

Why Purchase the Report?

• To visualize the Global Antithrombin Market segmentation based on the usage, type, route of administration, source, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of antithrombin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Antithrombin Market Report would Provide Approximately 49 Tables, 53 Figures, And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Usage
• 3.2. Snippet by Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Source
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Usage

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 8.1.2. Market Attractiveness Index, By Usage
• 8.2. Therapeutics*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diagnostics
• 8.4. Research
• 8.5. Other

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Anticoagulant*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Antiplatelet
• 9.4. Thrombolytic Drug

10. By Route of Administration

• 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
• 10.1.2. Market Attractiveness Index, By Route of Administration
• 10.2. Oral*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Parenteral

11. By Source

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
• 11.1.2. Market Attractiveness Index, By Source
• 11.2. Human*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Recombinant Goat Milk
• 11.4. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. The U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. The U.K.
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.7.1. Brazil
    • 12.4.7.2. Argentina
    • 12.4.7.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. CSL Limited*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Grifols SA
• 14.3. Takeda Pharmaceuticals
• 14.4. Octapharma AG
• 14.5. LFB USA
• 14.6. Axis-Shield Plc
• 14.7. Siemens AG
• 14.8. Thermo Fisher Scientific
• 14.9. Lee Biosolutions Inc.
• 14.10. BDI Pharma

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us